SCHEDULE: RTW Investments Cuts Exagen Stake Below 5%

RTW Investments and Dr. Roderick Wong have reduced their beneficial ownership in Exagen Inc. to 4.9% of common stock, as reported in their latest Schedule 13G amendment.

Summary

• RTW Investments, LP and Roderick Wong, M.D. filed an Amendment No. 6 to Schedule 13G regarding their holdings in Exagen Inc.
• They beneficially own an aggregate of 1,148,768 shares of Exagen Inc. Common Stock.
• This ownership represents 4.9% of the class of securities, a reduction from previous filings that placed them above the 5% threshold.
• The reported beneficial ownership includes warrants to purchase 358,306 shares, limited by a 4.99% beneficial ownership cap.
• The percentage is calculated based on 22,663,099 shares outstanding as of October 31, 2025.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a moderately negative signal, as a significant institutional investor has reduced its stake below the 5% reporting threshold, potentially indicating a loss of conviction or a strategic exit.

Negatives

• RTW Investments and Roderick Wong have reduced their beneficial ownership in Exagen Inc. to 4.9%, indicating a decreased conviction or a strategic portfolio adjustment.
• Falling below the 5% threshold means they are no longer required to file Schedule 13G, potentially reducing transparency on their future holdings unless they increase above 5% again.

Risks

• A significant institutional investor reducing its stake could signal concerns about the company's future performance or valuation.
• The reduction in ownership might put downward pressure on the stock price due to perceived lack of institutional confidence.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that institutional investor movements, especially by specialized healthcare funds like RTW Investments, are closely watched in the biotechnology and diagnostics sector. A reduction in stake by a prominent investor can sometimes precede or reflect broader industry trends or specific concerns about a company's competitive position or pipeline.

Stakeholder Impact

• Shareholders: May interpret the reduction in institutional ownership as a negative signal, potentially leading to selling pressure and a decrease in share price.
• Company Management: Might need to address investor concerns if the reduction is perceived as a lack of confidence in the company's strategy or performance.

Key Dates

Recommendation

The reduction of a significant institutional stake below the 5% threshold by RTW Investments, a specialized healthcare investor, signals a potential loss of confidence or a strategic divestment. This action could lead to negative market sentiment and downward pressure on Exagen Inc.'s stock price, making a 'sell' recommendation prudent for investors seeking to mitigate potential losses or reallocate capital.

Keywords

Exagen Inc., RTW Investments, Roderick Wong, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Stake Reduction, Biotechnology, Healthcare